Company / Capital Expenditures
Denali Therapeutics Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$9.5M
FY2025
5-year range
$3.1M / $17.9M
FY2021-FY2025
Trend
-40.3%
vs FY2024
Sector context
#61 of 194
Health Care
What the data says
At $10M, Denali Therapeutics Inc.'s capital expenditures ranks #61 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $3M in FY2019 to $18M in FY2021.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of +22.9%.
Declined from $13M to $10M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +45.3%
- 5-Year CAGR
- +22.9%
- 10-Year CAGR
- -
Sector benchmark
#61 of 194 in Health CareTop 31% of 194This company $9.5M Sector average $117.5M
▼
-91.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +22.9%, indicating consistent growth.
- In FY2025, capital expenditures decreased 40.3% year-over-year.
- Ranks #61 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5M | -40.3% |
| FY2024 | $15.9M | +23.0% |
| FY2023 | $12.9M | +318.1% |
| FY2022 | $3.1M | -82.7% |
| FY2021 | $17.9M | +428.1% |
| FY2020 | $3.4M | +18.0% |
| FY2019 | $2.9M | -53.1% |
| FY2018 | $6.1M | +113.4% |
| FY2017 | $2.9M | -53.1% |
| FY2016 | $6.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026